Evaxion Biotech Receives Regulatory Clearance to Initiate Phase II Trial of EVX-01 in Combination with KEYTRUDA^® for Treatment of Melanoma

Evaxion Biotech, Inc.announced it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®